Relevance of B3 lesions in breast diagnosis – frequency and therapeutic consequencesArticle in several languages: English | deutsch
14 September 2018 (online)
With improvements in breast imaging and minimally invasive interventions, detection of early breast cancer has increased. However, with the improved diagnostic capabilities, the risk of false-positive benign lesions as well as lesions classified as B3 by histopathology has also increased. Varying rates of malignancies are associated with B3 lesions, raising the question of whether such lesions should always be surgically removed. The results of our retrospective analysis should assist in this decision-making process.
307 core needle or vacuum-assisted needle biopsies in which B3 lesions were found were examined. The most common lesions were intraductal papillomas (44 %), atypical ductal hyperplasia (22.8 %), flat epithelial atypia (9.4 %), phyllodes tumours (6.5 %), radial scars (5.9 %), LIN 1 (4.9 %), complex fibroadenomas (3.3 %) and LIN 2 (1.6 %). The frequencies depended considerably on whether the tissue was obtained by core biopsy or vacuum biopsy. Stereotactic vacuum biopsy was generally performed in the case of microcalcification not apparent on sonography. Lesions visible on ultrasound had core needle biopsy.
Surgery was performed in 254 cases and a malignancy was found in 27.2 % on the final histopathology. Malignancy was found in 24.6 % of 114 cases initially diagnosed as intraductal papilloma. Similarly, cancer was discovered in 48.4 % of the 62 cases of atypical ductal hyperplasia, in 2.4 % of the 41 cases of flat epithelial atypia, complex fibroadenoma and phyllodes tumour, in 20.7 % of the 29 cases of LIN 1 and radial scar as well as in 50 % of the 8 cases of LIN 2, adenomyoepithelioma and atypical apocrine metaplasia.
These data indicate the necessity for complete surgical removal of a B3 lesion when it is discovered using the core needle or vacuum-assisted biopsy technique. The decision not to perform surgery can be made when the risk of associated malignancy is deemed low in the clinical pathology conference, but careful follow-up is essential.
Key wordsB3 lesions - uncertain malignant potential - open breast biopsy - breast cancer risk - interventional diagnostics
- 1 Bettendorf U, Fisseler-Eckhoff A. Die Rolle des Pathologen im Mammografiescreening. Der Pathologe 2009; 30 (01) 20-30
- 2 Amendoeira I. Quality assurance guidelines for pathology: Cytological and histological non-operative procedures. In: Perry N, Broeders M, de Wolf C. et al. Eds. European guidelines for quality assurance in breast cancer screening and diagnosis. 4th Luxembourg: Office for Official Publications of the European Communities; 2006: 221-256
- 3 Aulmann S. B3-Läsionen – was ist das?. Med Review 2011; 12: 17
- 4 Böcker W, Kreipe H. Kapitel 42: Mamma. In: Böcker W, Denk H, Heitz PU. et al. Hrsg Pathologie. 5. Aufl. München: Urban und Fischer; 2012: 811-826
- 5 Bianchi S, Caini S, Renne G. et al. Positive predictive value for malignancy on surgical excision of breast lesions of uncertain malignant potential (B3) diagnosed by stereotactic vacuum-assisted needle core biopsy (VANCB): a large multi-institutional study in Italy. Breast (Edinburgh, Scotland) 2011; 20 (03) 264-270
- 6 Houssami N, Ciatto S, Bilous M. et al. Borderline breast core needle histology: predictive values for malignancy in lesions of uncertain malignant potential (B3). Br J Cancer 2007; 96 (08) 1253-1257
- 7 Ciatto S, Houssami N, Ambrogetti D. et al. Accuracy and underestimation of malignancy of breast core needle biopsy: the florence experience of over 4000 consecutive biopsies. Breast cancer research and treatment 2007; 101: 291-307
- 8 Pagni F, Bosisio FM, Salvioni D. et al. Application of the British National Health Service Breast Cancer Screening Programme classification in 226 breast core needle biopsies: correlation with resected specimens. Annals of diagnostic pathology 2012; 16 (02) 112-118
- 9 Schulz-Wendtland R, Aichinger U, Kramer S. et al. Sonographical breast biopsy: how many core biopsy specimens are needed?. Fortschr Röntgenstr 2003; 175 (01) 94-98
- 10 El-Sayed ME, Rakha EA, Reed J. et al. Audit of performance of needle core biopsy diagnoses of screen detected breast lesions. European journal of cancer 2008; 44 (17) 2580-2586
- 11 Willems SM, van Deurzen CH, van Diest PJ. Diagnosis of breast lesions: fine-needle aspiration cytology or core needle biopsy? A review. Journal of clinical pathology 2012; 65 (04) 287-292
- 12 Buchberger W, Niehoff A, Obrist P. et al. Sonographically guided core needle biopsy of the breast: technique, accuracy and indications. Der Radiologe 2002; 42 (01) 25-32
- 13 Rajan S, Shaaban AM, Dall BJG. et al. New patient pathway using vacuumassisted biopsy reduces diagnostic surgery for B3 lesions. Clinical radiology 2012; 67 (03) 2449
- 14 Fahrbach K, Sledge I, Cella C. et al. A comparison of the accuracy of two minimally invasive breast biopsy methods: a systematic literature review and meta-analysis. Archives of gynecology and obstetrics 2006; 274 (02) 63-73
- 15 Rageth CJ, OʼFlynn EAM, Comstock C. et al. First International Consensus Conference on lesions of uncertain malignant potential in the breast (B3 lesions). Breast Cancer Res Treat 2016; 159 (02) 203-213
- 16 Leitlinienprogramm Onkologie: S3-Leitlinie Früherkennung, Diagnose, Therapie und Nachsorge des Mammakarzinoms, Version 4.0, 2017 AWMF Reg. Nr. 032-0450L.
- 17 Empfehlungen der AGO zur Diagnostik und Therapie von Patientinnen mit primärem und metastasiertem Brustkrebs. AGO Kommission Mamma der DGGG und DKG; 2018
- 18 Hahn M, Krainick-Strobel U, Toellner T. et al. Interdisciplinary consensus recommendations for the use of vacuum-assisted breast biopsy under sonographic guidance: first update 2012. Ultraschall in der Medizin 2012; 33 (04) 366-371
- 19 Hahn M, Fischbach E, Fehm T. et al. Ist die Mammabiopsie ausreichend finanziert? Eine Prozesskosten & Erlösbetrachtung. Fortschr Röntgenstr 2011; 183: 347-357